EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Therapeutic drug monitoring in adolescents with anorexia nervosa for safe treatment with adjunct olanzapine

Andreas Karwautz iD, Michael Zeiler iD, Julia Schwarzenberg, Dunja Mairhofer, Michaela Mitterer, Stefanie Truttmann, Julia Philipp, Doris Koubek, Maria Glüder, Gudrun Wagner, Anouk Malcher, Gabriele Schöfbeck und 14 weitere

European Eating Disorders Review · 2024

DOI: 10.1002/erv.3022 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Eating Disorders Review, 2024. Verfasst von Andreas Karwautz und 25 weiteren Autor:innen. Beteiligte Einrichtung: Eating Disorders Care and Research Unit, Department of Child and Adolescent Psychiatry, Medical University of Vienna, Wien, Austria. Hauptthemen laut MEDLINE: Anorexia Nervosa, Olanzapine, Drug Monitoring, Antipsychotic Agents. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Bundesinstitut für Arzneimittel und Medizinprodukte, German Federal Ministry of Education and Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Medication is commonly used in anorexia nervosa (AN) despite largely missing high grade evidence. Olanzapine (OLZ) is the best‐evidenced substance used off‐label in this group, with conflicting outcome regarding BMI, clinical and safety parameters. Therefore, it is important to strictly assure quality of treatment with OLZ in AN by using ‘Therapeutic Drug Monitoring’ according to AGNP‐guidelines, including serum levels and adverse drug reactions (ADRs) to support safety for adolescents with AN and attempt to generate an initial age‐ and disorder‐specific therapeutic reference range.

Method

Sixty‐five adolescents with AN (aged 10–18) treated with OLZ (98% female; 97.5% AN‐restricting‐type) were prospectively observed, ADRs reported, and correlations between dosage and serum levels measured at trough level were calculated, a preliminary therapeutic range defined.

Results

Mean dosage of OLZ was 8.15 (SD: 2.91) mg and 0.19 (SD: 0.07) mg/kg respectively, average concentration was 26.57 (SD: 13.46) ng/mL. Correlation between daily dosage/dosage per kg and serum level was 0.72 (** p < 0.001)/0.65 (** p < 0.001), respectively. ADRs with impairment were rare (6.3%). 75% improved clinically (CGI). BMI increased significantly by 1.5 kg/m 2 ( t = 10.6, p < 0.001). A preliminary therapeutic reference range is 11.9 and 39.9 ng/mL.

Conclusions

OLZ in the hands of specialists is a well‐tolerated and safe treatment adjunct for adolescents with AN.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anorexia NervosaOlanzapineDrug MonitoringAntipsychotic AgentsHumansAdolescentFemaleMaleChildBenzodiazepinesProspective Studies

Stichwörter der Autor:innen

TDMadolescentsadverse drug reactionsanorexia nervosaolanzapine

Substanzen

OlanzapineAntipsychotic AgentsBenzodiazepines

Autor:innen und Institutionen

  • Eating Disorders Care and Research Unit, Department of Child and Adolescent Psychiatry, Medical University of Vienna, Wien, Austria.
  • CIO Marburg GmbH, Fronhausen, Germany.
  • Parklandklinik, Bad Wildungen, Germany.
  • Department of Child and Adolescent Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, Mannheim, Germany.
  • Department of Child and Adolescent Psychiatry and Psychotherapy, University Medical Center Freiburg, Freiburg, Germany.
  • Berlin Department of Child and Adolescent Psychiatry, Psychosomatic Medicine and Psychotherapy, Charité University Medical Center, Berlin, Germany.

ORCID-Profile: Andreas Karwautz, Michael Zeiler, Clarissa Laczkovics, Karin Egberts

Förderung

  • Bundesinstitut für Arzneimittel und Medizinprodukte
  • German Federal Ministry of Education and Research

Zitieren

APA

Karwautz, A., Zeiler, M., Schwarzenberg, J., Mairhofer, D., Mitterer, M., Truttmann, S., Philipp, J., Koubek, D., Glüder, M., Wagner, G., Malcher, A., Schöfbeck, G., Laczkovics, C., Rock, H. W., Zanko, A., Imgart, H., Banaschewski, T., Fleischhaker, C., Correll, C. U., …, & Gerlach, M. (2024). Therapeutic drug monitoring in adolescents with anorexia nervosa for safe treatment with adjunct olanzapine. European Eating Disorders Review. https://doi.org/10.1002/erv.3022

Vancouver

Karwautz A, Zeiler M, Schwarzenberg J, Mairhofer D, Mitterer M, Truttmann S, et al. Therapeutic drug monitoring in adolescents with anorexia nervosa for safe treatment with adjunct olanzapine. European Eating Disorders Review. 2024. doi:10.1002/erv.3022

BibTeX
@article{Karwautz2024,
  author = {Karwautz, Andreas and Zeiler, Michael and Schwarzenberg, Julia and Mairhofer, Dunja and Mitterer, Michaela and Truttmann, Stefanie and Philipp, Julia and Koubek, Doris and Glüder, Maria and Wagner, Gudrun and Malcher, Anouk and Schöfbeck, Gabriele and Laczkovics, Clarissa and Rock, Hans W and Zanko, Annika and Imgart, Hartmut and Banaschewski, Tobias and Fleischhaker, Christian and Correll, Christoph U and Wewetzer, Christoph and Walitza, Susanne and Taurines, Regina and Fekete, Stefanie and Romanos, Marcel and Egberts, Karin and Gerlach, Manfred},
  title = {Therapeutic drug monitoring in adolescents with anorexia nervosa for safe treatment with adjunct olanzapine},
  journal = {European Eating Disorders Review},
  year = {2024},
  doi = {10.1002/erv.3022}
}
Kostenlos starten →